Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Latest Pharmaceuticals and Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals, Inc. Stock News

As of September 4, 2026, Prestige Consumer Healthcare Inc. had a $2.5 billion market capitalization, compared to the Pharmaceuticals median of $674.5 million. Prestige Consumer Healthcare Inc.’s stock is down 15.3% in 2026, down 0.4% in the previous five trading days and down 21.71% in the past year.

Currently, Prestige Consumer Healthcare Inc.’s price-earnings ratio is 14.6. Prestige Consumer Healthcare Inc.’s trailing 12-month revenue is $1.1 billion with a 15.6% net profit margin. Year-over-year quarterly sales growth most recently was 6.5%. Analysts expect adjusted earnings to reach $4.568 per share for the current fiscal year. Prestige Consumer Healthcare Inc. does not currently pay a dividend.

As of September 4, 2026, Amphastar Pharmaceuticals, Inc. had a $986.0 million market cap, putting it in the 45th percentile of all stocks. Amphastar Pharmaceuticals, Inc.’s stock is down 13.4% in 2026, up 5.3% in the previous five trading days and down 20.59% in the past year.

Currently, Amphastar Pharmaceuticals, Inc.’s price-earnings ratio is 13.7. Amphastar Pharmaceuticals, Inc.’s trailing 12-month revenue is $730.0 million with a 10.8% net profit margin. Year-over-year quarterly sales growth most recently was 5.4%. Analysts expect adjusted earnings to reach $2.972 per share for the current fiscal year. Amphastar Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
Prestige Consumer Healthcare Inc.	PBH	B
Amphastar Pharmaceuticals, Inc.	AMPH	A

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Prestige Consumer Healthcare Inc. has a Value Score of 71, which is Value. Amphastar Pharmaceuticals, Inc. has a Value Score of 91, which is Deep Value.

The Value Stock Winner: Amphastar Pharmaceuticals, Inc.

As you can clearly see from the Value Grade breakdown above, Amphastar Pharmaceuticals, Inc. is considered to have better value than Prestige Consumer Healthcare Inc.. For investors who focus solely on a company’s valuation, Amphastar Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc.’s Quality Grades

Company	Ticker	Quality
Prestige Consumer Healthcare Inc.	PBH	C
Amphastar Pharmaceuticals, Inc.	AMPH	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Prestige Consumer Healthcare Inc. has a Quality Score of 57, which is Average. Amphastar Pharmaceuticals, Inc. has a Quality Score of 74, which is Strong.

The Quality Grade Winner: Amphastar Pharmaceuticals, Inc.

As you can clearly see from the Quality Grade breakdown above, Amphastar Pharmaceuticals, Inc. has a better overall quality grade than Prestige Consumer Healthcare Inc.. For investors who are looking for companies with higher quality than others in the same industry, Amphastar Pharmaceuticals, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
Prestige Consumer Healthcare Inc.	PBH	D
Amphastar Pharmaceuticals, Inc.	AMPH	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Prestige Consumer Healthcare Inc. has a Momentum Score of 34, which is Weak. Amphastar Pharmaceuticals, Inc. has a Momentum Score of 39, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals or Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals or Inc. is the better investment when it comes to momentum.

Other Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc. Grades

In addition to Momentum, Quality and Value, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals or Inc. Stock?

Overall, Prestige Consumer Healthcare Inc. stock has a Value Score of 71, Momentum Score of 34 and Quality Score of 57.

Amphastar Pharmaceuticals, Inc. stock has a Value Score of 91, Momentum Score of 39 and Quality Score of 74.

Comparing Prestige Consumer Healthcare Inc., Amphastar Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.